Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
- None.
- None.
The development of FHD-909 as a BRM (SMARCA2) selective inhibitor by Foghorn Therapeutics represents a significant advancement in targeted cancer therapy. The emphasis on BRG1 mutated cancers, particularly non-small cell lung cancer (NSCLC), is notable since these mutations can be difficult to treat with conventional therapies. The preclinical data suggesting favorable tolerability and dose-dependent activity indicates that FHD-909 could potentially fill a treatment gap for patients with these specific mutations.
From a medical research perspective, FHD-909's progress is a promising sign that Foghorn’s drug discovery engine is capable of producing viable candidates for difficult-to-target oncogenic drivers. The potential impact on patient outcomes could be substantial, especially if the drug's efficacy translates from preclinical models to human trials. The specificity of FHD-909 in targeting BRM mutations could also lead to a more personalized approach in cancer treatment, aligning with the broader industry trend towards precision medicine.
As an oncologist, the prospect of introducing a first-in-class BRM selective inhibitor into the treatment landscape is exciting. The BRG1 mutation in NSCLC is associated with a poor prognosis and the development of a drug like FHD-909 could potentially improve survival rates. The fact that this drug has shown preclinical efficacy raises hope for a new therapeutic option that might offer benefits over existing treatments, such as reduced side effects or improved targeting of cancer cells.
However, it is important to approach these results with cautious optimism. The transition from preclinical success to clinical efficacy is not guaranteed and the safety profile observed in preclinical studies may differ in human subjects. Additionally, the long-term effects and potential resistance mechanisms are unknown at this stage and will require extensive investigation.
In terms of financial implications, the announcement of positive preclinical data for FHD-909 and related programs could have a positive impact on Foghorn Therapeutics' stock valuation. Investors often respond favorably to advancements in a company's pipeline, especially when it concerns a potential first-in-class therapy with a broad application like NSCLC. The market for cancer treatments is highly competitive, but also very lucrative and an effective new drug can lead to significant revenue.
However, it is important to consider the regulatory risks and the high costs associated with bringing a new drug to market. The IND filing is projected for Q2 2024, which means there is still a considerable amount of time before potential FDA approval and commercialization. Investors should weigh the potential of FHD-909 against the inherent risks of drug development, including the possibility of failure in clinical trials or delays in regulatory approval.
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024
Robust preclinical monotherapy anti-tumor activity for both selective CBP and selective EP300 degrader programs
Progress with FHD-909, selective CBP, and selective EP300 degrader programs further validates Foghorn’s drug discovery engine
Conference call and webcast today at 5 pm ET / 2 pm PT
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.
“We are pleased with the encouraging data for our highly selective and potent drug candidates, which address historically very challenging cancer targets," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors. We believe FHD-909 offers a potential new approach for the treatment of cancer. The primary target patient population is BRG1 mutated non-small cell lung cancer (NSCLC), which accounts for about
Steve Bellon Ph.D., Chief Scientific Officer of Foghorn Therapeutics added, “CBP and EP300 are nearly identical proteins which has made targeted specific approaches challenging. Our selective CBP program demonstrates significant tumor growth inhibition in solid tumors without thrombocytopenia or anemia that have been observed with dual CBP/EP300 inhibition. Our selective EP300 program, which is earlier in development, also demonstrates promising preclinical efficacy with no thrombocytopenia or negative effects on megakaryocyte viability, which are often seen in dual approaches. Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates. These are exciting achievements in the development of protein degraders for major cancer types, and we look forward to further progress across these important targets.”
Presentation Highlights
FHD-909 Program
BRM and BRG1 are highly homologous and mutually exclusive subunits of the BAF complex. BRG1 mutations occur in a variety of tumor types, including approximately
Poster 3230 / 14: Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers
Preclinical data presented at AACR support FHD-909 as an oral, novel, potent and selective BRM inhibitor with robust anti-tumor monotherapy activity:
- ~ 30-fold selectivity for BRM inhibition over BRG1 in cell-based assays
- Dose-dependent and robust tumor growth inhibition and regression as a monotherapy in multiple BRG1 mutant xenograft models
- Favorable tolerability with dose dependent modulation of BRM target genes in vivo
- Lilly plans to file an IND application for potential first-in-class orally bioavailable, selective BRM inhibitor, FHD-909, with initial focus in BRG1 mutated NSCLC in Q2 2024
Selective CBP and Selective EP300 Degrader Programs
CBP and EP300 are paralog histone acetyltransferases involved in many cellular processes. Dysregulation of one or both is implicated in various cancer types, and functional genomic screens have suggested a synthetic lethal relationship in tumor cells. Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins. Additionally, dual inhibition of CBP/EP300 has led to hematopoietic toxicity.
Selective CBP Program
Poster 6067 / 26: Identification of selective CBP degraders with robust preclinical PK, PD, efficacy, and safety across solid tumor indications
Preclinical pharmacodynamic and pharmacokinetic data presented at AACR support the identification of potent and selective CBP degraders with anti-tumor activity across various EP300 mutant cell lines from multiple indications:
- Deep and sustained CBP degradation leading to significant tumor growth inhibition in mouse xenograft solid tumor models
- Robust monotherapy anti-tumor activity that was not associated with significant body weight loss
- In vivo, no evidence of thrombocytopenia, which is attributed to the sparing of megakaryocytes, nor evidence of anemia
- Long-acting CBP-selective protein degrader formulations with first-in-class potential for patients with tumors harboring EP300 mutations
Selective EP300 Program
Poster 6064 / 23: Discovery of potent and selective EP300 degraders with anti-cancer activity
Preclinical pharmacodynamic and pharmacokinetic data presented at AACR support the identification of potent and selective EP300 degraders with anti-tumor activity in prostate and hematological malignancies:
- Reduced growth of androgen receptor positive prostate cells and attenuated androgen signaling
- Reduced the growth of prostate cancer xenograft tumors in mice
- Broad anti-tumor activity across a panel of multiple myeloma and DLBCL cell lines
- In vivo efficacy demonstrated in a DLBCL model
- Well tolerated in vivo with no observed decrease in platelet levels, additionally mechanistic studies ex vivo show no effects on megakaryocyte viability at pharmacologically relevant concentrations
Conference Call and Webcast Information
Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review pipeline updates. The dial-in number for the conference call is 1-877-704-4453 (U.S./Canada) or 1-201-389-0920 (international). The conference ID for all callers is 13745314. The live webcast and replay may be accessed under Events and Presentations in the Investors section of the Foghorn’s website, www.foghorntx.com, and will be available for up to 30 days.
About FHD-909
FHD-909 is a highly potent, allosteric and orally available small molecule that selectively inhibits the ATPase activity of BRM over its closely related paralog BRG1, two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, tumors with mutations in BRG1 rely on BRM for BAF function. FHD-909 has shown significant anti-tumor activity across multiple BRG1-mutant lung tumor models.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts, including statements relating to FHD-286, FHD-909 and its selective CBP and selective EP300 degrader programs, and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contacts:
Greg Dearborn, Foghorn Therapeutics Inc. (Investors)
gdearborn@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com
Adam Silverstein, ScientPR (Media)
adam@scientpr.com
Peter Kelleher, LifeSci Advisors (Investors)
pkelleher@lifesciadvisors.com
FAQ
What is the significance of the preclinical data announced by Foghorn Therapeutics Inc. at the 2024 AACR Annual Meeting?
When is the IND filing for FHD-909 expected to take place?
What type of cancers is FHD-909 primarily targeting?
What is the focus of Foghorn Therapeutics Inc.'s drug discovery engine?
When is the conference call and webcast scheduled for further pipeline updates?
